Prospective real world observational multi-center study in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Campania, Italy

Multi Center Study ◽

Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study

10.26226/morressier.59a3e8b6d462b8028d8951f5 ◽

2017 ◽

Cited By ~ 1

Author(s):

Jacob Sloane

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Real World ◽

Dimethyl Fumarate ◽

Effect Study ◽

The Real ◽

Delayed Release ◽

Relapsing Remitting ◽

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis

Neurology and Therapy ◽

10.1007/s40120-019-00174-3 ◽

2019 ◽

Vol 9 (1) ◽

pp. 85-92

Author(s):

Michelle Allan ◽

Lindsay Grant

Keyword(s):

Multiple Sclerosis ◽

Retrospective Analysis ◽

Real World ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

European Journal of Neurology ◽

10.1111/j.1468-1331.2009.02728.x ◽

2009 ◽

Vol 17 (1) ◽

pp. 31-37 ◽

Cited By ~ 60

Author(s):

N. Putzki ◽

O. Yaldizli ◽

M. Mäurer ◽

S. Cursiefen ◽

S. Kuckert ◽

...

Keyword(s):

Multiple Sclerosis ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Relapsing Remitting ◽

German Speaking ◽

Multi Center Study ◽

Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study

Current Medical Research and Opinion ◽

10.1080/03007995.2017.1380616 ◽

2017 ◽

Vol 33 (12) ◽

pp. 2099-2106 ◽

Cited By ~ 5

Author(s):

Frank R. Ernst ◽

Peri Barr ◽

Riad Elmor ◽

Schiffon L. Wong

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Dimethyl Fumarate ◽

Treatment Patterns ◽

Interferon Β ◽

Relapsing Remitting ◽

Treatment with Delayed-release Dimethyl Fumarate is Associated with Fewer Relapses versus Glatiramer Acetate in Patients with Relapsing Remitting Multiple Sclerosis: Real-world Comparative Effectiveness Analyses from the EFFECT Study

10.26226/morressier.59a3edabd462b8028d89517d ◽

2017 ◽

Author(s):

Andrew Chan

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Real World ◽

Comparative Effectiveness ◽

Dimethyl Fumarate ◽

Effect Study ◽

Delayed Release ◽

Relapsing Remitting ◽

Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study

NeuroImage Clinical ◽

10.1016/j.nicl.2012.11.009 ◽

2013 ◽

Vol 2 ◽

pp. 120-131 ◽

Cited By ~ 42

Author(s):

Ponnada A. Narayana ◽

Koushik A. Govindarajan ◽

Priya Goel ◽

Sushmita Datta ◽

John A. Lincoln ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cortical Thickness ◽

Relapsing Remitting ◽

Multi Center Study ◽

FP33-WE-02 Efficacy of natalizumab in second-line therapy of relapsing remitting multiple sclerosis: results from a multi-center study in German speaking countries

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(09)70440-x ◽

2009 ◽

Vol 285 ◽

pp. S109

Author(s):

N. Putzki ◽

Y. Oezguer ◽

M. Mäurer ◽

S. Cursiefen ◽

S. Kuckert ◽

...

Keyword(s):

Multiple Sclerosis ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Relapsing Remitting ◽

German Speaking ◽

Multi Center Study ◽

Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation

10.26226/morressier.5b719e475aff74008ae4cbeb ◽

2018 ◽

Author(s):

Maria Davydovskaya

Keyword(s):

Multiple Sclerosis ◽

Russian Federation ◽

Real World ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Real World Setting ◽

Relapsing Remitting ◽

A Real-world Comparison of Infection Rate and Lymphocyte Counts Among Relapsing: Remitting Multiple Sclerosis Patients 50 Years or Older Treated with Subcutaneous Interferon Beta-1a Or Dimethyl Fumarate

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2018.10.089 ◽

2018 ◽

Vol 26 ◽

pp. 259

Author(s):

B. Hayward ◽

S. Cardoso ◽

M. Grosso ◽

S. Ansari ◽

S. Napoli

Keyword(s):

Multiple Sclerosis ◽

Infection Rate ◽

Real World ◽

Interferon Beta ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Relapsing-Remitting Multiple Sclerosis Patients On Dimethyl Fumarate Reported Less Physical And Psychological Disease Impact In The Real World Compared With Patients On Platform Therapies

Value in Health ◽

10.1016/j.jval.2017.08.2652 ◽

2017 ◽

Vol 20 (9) ◽

pp. A887

Author(s):

M Huang ◽

J Pike ◽

W Huang ◽

E Jones

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Dimethyl Fumarate ◽

The Real ◽

Relapsing Remitting ◽

Disease Impact ◽

Multiple Sclerosis Patients ◽